<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">WNT2B — Wnt Family Member 2B</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>WNT2B</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Wnt Family Member 2B</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>7p14.3</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/7482" target="_blank">7482</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000119041" target="_blank">ENSG00000119041</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q99836" target="_blank">Q99836</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Cancer</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain, Lung, Testis, Ovary, Pancreas</td>
</tr>
<tr>
<th class="infobox-subheader" colspan="2">Key Pathways</th>
</tr>
<tr>
<td colspan="2" style="font-size:0.85em">Wnt/β-Catenin, Wnt/PCP, Planar Cell Polarity</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
<table class="infobox infobox-gene">
<tr>
<th class="infobox-header" colspan="2">WNT2B — Wnt Family Member 2B</th>
</tr>
<tr>
<td class="label">Symbol</td>
<td><strong>WNT2B</strong></td>
</tr>
<tr>
<td class="label">Full Name</td>
<td>Wnt Family Member 2B</td>
</tr>
<tr>
<td class="label">Chromosome</td>
<td>7p14.3</td>
</tr>
<tr>
<td class="label">NCBI Gene</td>
<td><a href="https://www.ncbi.nlm.nih.gov/gene/7482" target="_blank">7482</a></td>
</tr>
<tr>
<td class="label">Ensembl</td>
<td><a href="https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000119041" target="_blank">ENSG00000119041</a></td>
</tr>
<tr>
<td class="label">UniProt</td>
<td><a href="https://www.uniprot.org/uniprot/Q99836" target="_blank">Q99836</a></td>
</tr>
<tr>
<td class="label">Diseases</td>
<td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Cancer</td>
</tr>
<tr>
<td class="label">Expression</td>
<td>Brain, Lung, Testis, Ovary, Pancreas</td>
</tr>
<tr>
<th class="infobox-subheader" colspan="2">Key Pathways</th>
</tr>
<tr>
<td colspan="2" style="font-size:0.85em">Wnt/β-Catenin, Wnt/PCP, Planar Cell Polarity</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">1 edges</a></td>
</tr>
</table>
WNT2B (Wnt Family Member 2B), also known as WNT13, is a member of the Wnt family of secreted signaling molecules that play crucial roles in embryonic development, tissue homeostasis, and disease pathogenesis. WNT2B is expressed in the developing nervous system and adult brain, where it regulates neurogenesis, neuronal differentiation, and synaptic plasticity. Dysregulation of WNT2B signaling has been implicated in neurodegenerative diseases including Alzheimer's disease and Parkinson's disease, as well as in various cancers[@macdonald2009].
The Wnt signaling pathway is an evolutionarily conserved system that controls cell fate, proliferation, and differentiation. WNT2B is one of 19 Wnt proteins in humans, each with distinct expression patterns and functional properties. Unlike some other Wnt proteins, WNT2B can activate multiple branches of the Wnt signaling pathway, making its effects context-dependent and complex[@clevers2012].
The discovery of Wnt signaling as a key regulator of brain development and function has transformed our understanding of neurodevelopmental and neurodegenerative processes. WNT2B, as a brain-enriched Wnt ligand, occupies a special position in these regulatory networks.
The WNT2B gene is located on chromosome 7p14.3 and encodes a secreted protein of 395 amino acids. The gene structure is characteristic of the Wnt family, with a signal peptide for secretion and a conserved cysteine-rich domain involved in receptor binding.
The WNT2B gene spans approximately 7 kb of genomic DNA and consists of multiple exons. The coding sequence is highly conserved across species, reflecting the essential nature of Wnt signaling in development.
The promoter region contains several regulatory elements that control tissue-specific expression. These include binding sites for transcription factors active in neural progenitor cells and response elements for signaling pathways that modulate WNT2B expression.
WNT2B shows tissue-specific expression patterns that reflect its biological functions:
In the nervous system, WNT2B is expressed at highest levels during development, particularly in the developing forebrain and midbrain. In the adult brain, expression is maintained in the hippocampus, cerebral cortex, and subventricular zone, all regions where neurogenesis continues throughout life.
In peripheral tissues, significant expression is observed in the lung, where WNT2B regulates branching morphogenesis. Testis and ovary expression reflects roles in reproductive system development. Pancreatic expression suggests functions in endocrine regulation.
WNT2B expression is regulated at multiple levels:
Developmental signals control WNT2B expression during neurogenesis through transcription factor networks that include TCF/LEF family members and neural-specific regulators. Epigenetic modifications, particularly DNA methylation patterns, influence expression in different tissues and disease states. Environmental factors including cellular stress can modulate WNT2B levels.
The complexity of WNT2B regulation ensures appropriate spatial and temporal expression patterns that are essential for its functions in development and tissue maintenance.
The WNT2B protein is a secreted glycoprotein that functions as a signaling molecule in the extracellular space.
WNT2B contains several important structural elements that determine its function:
The N-terminal signal peptide enables secretion from producing cells, targeting the protein to the secretory pathway. The cysteine-rich domain contains ten conserved cysteine residues that form disulfide bonds, creating a compact structure essential for receptor interactions.
A lipid modification site involves palmitoylation on a conserved cysteine residue. This modification affects protein distribution, receptor binding, and signaling potency. The modification is reversible and can be regulated.
The C-terminal receptor binding regions interact with Frizzled receptors and co-receptors to initiate downstream signaling. Different regions of the protein may be involved in activating different pathway branches.
Wnt proteins present experimental challenges due to their hydrophobic nature. WNT2B is secreted and can act on neighboring cells through paracrine signaling or more distant cells through endocrine mechanisms.
The secretion process involves the Wntless protein, which is required for proper Wnt protein transport and release. Mutations affecting Wntless impair WNT2B secretion and function.
Extracellular distribution is modulated by heparan sulfate proteoglycans, which can sequester Wnt proteins and present them to target cells. Receptor presentation on target cell surfaces also affects distribution and signaling.
WNT2B activates multiple downstream pathways depending on receptor context and cellular environment. This versatility allows WNT2B to participate in diverse biological processes.
The canonical Wnt/β-catenin pathway is the most well-characterized Wnt signaling branch[@kahn2014]. WNT2B initiates this pathway by binding to Frizzled receptors and LRP5/6 co-receptors on the cell surface. This binding triggers Dishevelled phosphorylation and activation, which then inhibits the destruction complex.
The destruction complex normally phosphorylates β-catenin, targeting it for degradation. When inhibited, β-catenin accumulates and translocates to the nucleus. In the nucleus, β-catenin interacts with TCF/LEF transcription factors to activate target gene expression.
Canonical target genes include cell cycle regulators such as cyclin D1 and c-Myc, anti-apoptotic proteins including survivin, and stemness factors like Oct4 and Nanog. The expression of these genes drives proliferation, survival, and stem cell maintenance.
WNT2B also signals through non-canonical pathways that do not involve β-catenin:
The Wnt/Planar Cell Polarity (PCP) pathway controls cell polarity and tissue morphogenesis. This pathway involves Dishevelled and small GTPases, affecting cytoskeletal organization and cell movement. In the nervous system, PCP signaling influences neuronal migration and axon guidance.
The Wnt/Calcium pathway activates calcium-dependent signaling cascades. This pathway involves heterotrimeric G proteins and can activate calcineurin and CaMKII. In neurons, calcium signaling can modulate synaptic function and plasticity.
WNT2B plays important roles in nervous system development and function through its effects on cell proliferation, differentiation, and signaling.
During development, WNT2B regulates multiple aspects of neurogenesis[@inestrosa2015]:
Neural progenitor cell proliferation is controlled by WNT2B signaling, which maintains the stem cell pool while allowing controlled expansion. WNT2B gradients create patterns of proliferation that shape brain development.
Neuronal differentiation is directed by WNT2B, which influences the fate choices of neural progenitor cells. Different Wnt proteins, including WNT2B, can promote different neuronal fates.
Axon guidance is influenced by Wnt signaling through effects on growth cone navigation. WNT2B gradients provide directional cues that help axons find their targets.
Synaptogenesis, the formation of synaptic connections, is affected by WNT2B. Wnt signaling regulates the expression of synaptic proteins and the formation of functional synapses.
In the adult brain, WNT2B continues to play important roles:
Hippocampal neurogenesis, which continues in the adult brain, is regulated by WNT2B. This process is essential for certain forms of learning and memory, and its decline is associated with cognitive aging.
Synaptic plasticity, including long-term potentiation (LTP) and long-term depression (LTD), is modulated by WNT2B. Wnt signaling affects both the induction and maintenance of synaptic plasticity.
Circuit maintenance in the adult brain requires ongoing Wnt signaling. Dysregulation can contribute to circuit dysfunction and neuronal vulnerability.
WNT2B affects stem cell populations in several ways:
Neural stem cell maintenance is supported by WNT2B signaling, which keeps stem cells in a proliferative, undifferentiated state. Stem cell niches in the brain provide signals including WNT2B that maintain stem cell populations.
Regeneration potential may be influenced by WNT2B. The ability of the adult brain to regenerate after injury is limited, but Wnt signaling plays a role in the responses that do occur.
WNT2B signaling is implicated in AD pathogenesis through multiple interconnected mechanisms[@marchetti2013].
The relationship between amyloid pathology and Wnt signaling is complex and bidirectional. Amyloid-beta (Aβ) peptides, the hallmark of AD pathology, affect Wnt pathway activity. Aβ can inhibit Wnt signaling, creating a positive feedback loop where Aβ suppresses a pathway that would normally provide neuroprotection.
Conversely, Wnt signaling can modulate Aβ production and toxicity. Wnt/β-catenin signaling affects the expression of APP processing enzymes and can influence amyloidogenesis.
The crosstalk between these pathways has therapeutic implications. Restoring Wnt signaling might break the pathogenic cycle and provide neuroprotection.
WNT2B interacts with tau pathology through several mechanisms:
GSK3β regulation is central to this interaction. GSK3β is both a downstream target of Wnt signaling and the primary kinase responsible for tau hyperphosphorylation. When Wnt signaling is impaired, GSK3β activity increases, promoting tau pathology.
The balance between kinase and phosphatase activities affects tau phosphorylation status. Wnt signaling helps maintain this balance.
Aggregation of hyperphosphorylated tau into neurofibrillary tangles is influenced by cellular signaling states, including Wnt pathway activity.
Wnt signaling is essential for synaptic health:
At presynaptic terminals, Wnt signaling affects neurotransmitter release through modulation of vesicle cycling and release probability. Dysregulated WNT2B signaling impairs these processes.
At postsynaptic sites, Wnt signaling modulates the expression and trafficking of glutamate receptors, particularly NMDA receptors. This affects synaptic strength and plasticity.
LTP and LTD, the cellular correlates of learning and memory, are impaired when Wnt signaling is disrupted. This synaptic plasticity deficit underlies cognitive decline.
Wnt modulators are being explored for AD treatment:
Wnt activators could provide neuroprotection by restoring signaling homeostasis. Several small molecules have shown promise in preclinical models.
GSK3β inhibitors target the downstream consequences of Wnt dysfunction. These compounds are in various stages of development.
Combination approaches that address multiple aspects of AD pathogenesis, including amyloid, tau, and Wnt signaling, may be more effective than single-target strategies.
WNT2B contributes to PD through effects on dopaminergic neuron development, function, and survival[@zhang2021].
Wnt signaling is crucial for dopaminergic neuron development:
During development, Wnt signals are essential for midbrain dopaminergic neuron specification. WNT2B and other Wnt proteins create gradients that pattern the midbrain and specify neuronal fates.
In mature neurons, Wnt signaling supports survival and function. Dopaminergic neurons have specific vulnerability in PD, and impaired Wnt signaling may contribute to this vulnerability.
The substantia nigra pars compacta (SNc), the brain region most affected in PD, has particular dependencies on Wnt signaling for maintenance.
WNT2B modulates inflammatory responses in the brain:
Microglial activation is affected by Wnt signaling. WNT2B can promote anti-inflammatory microglial phenotypes, while dysregulation may contribute to chronic inflammation.
Cytokine production and signaling are modulated by Wnt pathways. This creates bidirectional communication between inflammatory processes and neuronal health.
Neuroprotection through anti-inflammatory effects is one mechanism by which Wnt signaling supports neuronal survival.
Wnt pathways interact with mitochondrial biology:
Mitochondrial biogenesis is regulated by PGC-1α, which is a downstream target of Wnt signaling. Impaired Wnt signaling affects mitochondrial health.
Mitochondrial dynamics, including fission and fusion, are influenced by Wnt signaling. These processes are essential for mitochondrial quality control.
Mitophagy, the selective autophagy of damaged mitochondria, involves Wnt pathway components. Impaired mitophagy is implicated in PD pathogenesis.
Aberrant WNT2B expression contributes to tumorigenesis in several cancer types[@zhan2017].
WNT2B acts as an oncogene in multiple contexts:
Enhanced cell proliferation results from canonical Wnt pathway activation. WNT2B-driven β-catenin target gene expression promotes cell cycle progression.
Cancer stem cell maintenance is supported by WNT2B signaling. Stemness factors that are Wnt targets help maintain the self-renewing population of cancer cells.
Migration and invasion are promoted through non-canonical Wnt pathways. This enables metastasis and tumor progression.
WNT2B is dysregulated in several common cancers:
In lung cancer, WNT2B is frequently overexpressed and associated with poor prognosis. Preclinical models show that WNT2B depletion reduces tumor growth.
In breast cancer, WNT2B expression correlates with aggressive disease. Therapeutic targeting is being explored.
In colorectal cancer, canonical Wnt signaling is commonly activated. WNT2B contributes to this activation in some cases.
In pancreatic cancer, WNT2B represents a potential therapeutic target. Combination approaches are in development.
Multiple approaches target Wnt signaling for therapeutic benefit:
Wnt inhibitors are primarily being developed for cancer applications. These include antibodies against Wnt proteins, small molecule inhibitors of Wnt secretion, and receptor blockers.
Secretion inhibitors target the Wntless protein required for Wnt release. These compounds block Wnt signaling at its source.
Receptor blockers targeting Frizzled proteins prevent Wnt-receptor interaction and downstream signaling.
For neurodegenerative diseases, different strategies are needed:
Wnt activators include small molecules that enhance Wnt signaling. These are being developed for AD, PD, and other conditions.
Gene therapy approaches using viral vectors could deliver Wnt ligands or Wnt pathway components to the brain. These approaches are in preclinical development.
Cell therapy combining stem cells with Wnt modulators may enhance therapeutic benefits.
Current research focuses on:
Achieving pathway specificity to avoid unwanted effects. Different Wnt proteins and receptors have different functions, and selective targeting is challenging.
Improving blood-brain barrier penetration for CNS delivery. Many promising compounds cannot reach their targets in the brain.
Identifying biomarkers for patient selection. Not all patients may benefit from Wnt-targeted approaches, and biomarkers could guide treatment choices.
Wnt2B knockout mice show developmental abnormalities, confirming the essential nature of this gene. However, some redundancy with other Wnt proteins limits the phenotype severity.
Transgenic models with reporter genes allow visualization of Wnt pathway activity. These models show dynamic patterns of activity during development and in adult tissues.
Disease models combining Wnt modulation with disease genes help clarify the role of Wnt signaling in specific pathologies.